-
Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion
•
Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and backed by the Chinese Academy of Sciences (CAS), has reportedly secured over RMB 100 million (USD 14.5 million) in strategic financing. The round was reportedly supported by Sinowisdom, Guangzhou Industrial Investment Fund, and Speedfox. The…
-
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
•
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the cell and gene therapy (CGT) sector, has reportedly secured RMB 100 million (USD 14.5 million) in a Series B financing round. The round was led by Dalton Venture, with additional investment from Qikun Fund and…
-
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
•
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
•
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800…
-
CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System
•
CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a regulatory study for its 7.5F 2D intracardiac ultrasound imaging system (ICE), successfully enrolling dozens of patients. This ultrasound catheter model is smaller than any currently marketed ICE products globally, nearing the industry’s design limits. The…
-
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
•
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing…
-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
•
Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of…
-
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week, revealing a 6% year-on-year increase in annual global revenues, reaching USD 45.8 billion at constant exchange rates. Oncology revenue surged by 21%, while cardiovascular, renal, and metabolism (CVRM) sales rose 18%. Respiratory and immunology (R&I)…
-
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
•
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with total product sales remaining unchanged at USD 26.9 billion. Amid a broad decline in demand for COVID-19 treatments, the company’s antiviral Veklury (remdesivir) sales could not offset the downturn, although HIV sales increased by 6%…
-
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
•
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining flat at USD 26.9 billion. The company’s financials were affected by a widespread downturn in demand for COVID-19 treatments, as its antiviral Veklury (remdesivir) sales offset growth in other areas. HIV sales reached USD 18.2…
-
Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
•
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual sales of USD 26.9 billion, reflecting a substantial 9% year-on-year (YOY) increase, primarily driven by volume growth. In an earnings call, CEO Robert Bradway highlighted that a remarkable 18 of the company’s medicines achieved record…
-
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
•
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20% year-on-year (YOY) increase in revenue, reaching USD 34.1 billion, as detailed in their Q4 2023 report released this week. This growth was substantially driven by the company’s metabolism drugs, indicating a recovery from the COVID-19…
-
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding foreign exchange effects, totaling $45.0 billion, according to its recently released financial report. The company’s global sales were bolstered by a 4% increase in in-line products, generating $34.3 billion, and a remarkable 76% surge in…
-
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
•
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will…
-
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest 1% year-on-year (YOY) increase in global sales at constant exchange rates (CER) to CHF 58.7 billion (USD 68.5 billion). This growth was primarily due to a 6% YOY expansion in the pharmaceutical business to CHF…
-
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the 9-month period ended December 31, 2023, reporting a revenue of JPY 3.2 trillion (USD 21.9 billion) with a 0.0% growth at constant exchange rates (CER). The company’s performance was impacted by declines in oncology, neuroscience,…
-
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
•
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the successful closure of a Series A++ financing round worth USD 10 million. The round was led by Med-Fine Capital, with participation from Puhua Leading Investment. The funds raised will be allocated towards the global promotion…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
